BioWorld

Aug. 8, 2006

Cabrellis' $27.5M Series A To Fund Three SCLC Trials

A Conforma Therapeutics Corp. spinout, barely three months old, closed a $27.5 million Series A financing to cover Phase II trials of its only product, Calsed, to treat small-cell lung cancer. (BioWorld Today) Read More

BioCryst, FDA Agree On SPA For Fodosine In Blood Cancer

New Analysis Shows ESC State Funding Not Enough

Nanoemulsion Platform Gets $30M Financing For NanoBio

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2026.

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...